- Entry Price, Stop Price, Target1 Price and Target2 Price will be sent to your phone/email
- Long and short trades are included in the 3 Day Reversal Swing Trading Strategy
- These alerts can be day traded using Target 1 for day trading
Stocks Gapping Up 2017-02-24
AXDX Accelerate Diagnostics (AXDX) said the U.S. Food and Drug Administration has granted marketing authorization for the Accelerate Pheno system and Accelerate PhenoTest blood culture kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples. The company noted that the Centers for Disease Control and Prevention estimate at least 2 million people each year are infected with antibiotic resistant bacteria across the U.S. In addition, antibiotic resistance contributes to the morbidity and mortality of healthcare-associated infections that kill an estimated 75,000 people annually.
AAOI Applied Optoelectronics (AAOI) reported late Thursday improved Q4 results from a year earlier that beat forecasts compiled by Capital IQ and issued upside guidance for Q1. AAOI was up over 11% in recent trade, above the top end of its 52-week range of $8.08 to $38.89 and on track to hit a new high in regular trade. The provider of fiber-optic network products said Q4 adjusted EPS was $0.84 per share, up from $0.22 per share a year earlier and five cents above the consensus.
EARS Auris Medical Holding AG (EARS) said the US Food and Drug Administration (FDA) granted the company Fast Track designation for AM-111 in the treatment of acute sensorineural (inner ear) hearing loss. The Fast Track program was created by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious conditions and fill an unmet medical need. The program's purpose is to get important new drugs to the patient earlier. A drug that receives Fast Track designation is granted more frequent access to the FDA to review the drug's development plan and may become eligible for priority review if relevant criteria are met. Additionally, Fast Track designation allows the sponsor to submit parts of the New Drug Application (NDA) for review on a rolling basis as data become available.
BIDU Baidu.com (BIDU) reported Q4 EPS of $0.93, ex-gain, $0.02 better than the analyst estimate of $0.91. Revenue for the quarter came in at $2.62 billion versus the consensus estimate of $2.67 billion. Baidu currently expects to generate total revenues in an amount ranging from RMB16.480 billion ($2.374 billion) to RMB17.030 billion ($2.453 billion) for the first quarter of 2017 (*** consensus is $2.47 billion), representing a 4.2% to 7.6% year-over-year increase. This forecast reflects Baidu's current and preliminary view, which is subject to change.
CEMP Cempra (CEMP) reported positive top-line results from a clinical study of oral fusidic acid in 716 patients with acute bacterial skin and skin structure infections (ABSSSI). The company said fusidic acid was well tolerated in the study, and achieved the primary endpoint, demonstrating non-inferiority of oral fusidic acid compared to oral linezolid for early clinical response in the intent to treat patient population.
FL Foot Locker (FL) reported Q4 EPS of $1.42, $0.10 better than the analyst estimate of $1.32. Revenue for the quarter came in at $2.11 billion versus the consensus estimate of $2.11 billion. Fourth quarter comparable-store sales increased 5.0 percent.
INWK InnerWorkings (INWK) reported Q4 EPS of $0.09, $0.02 better than the analyst estimate of $0.07. GUIDANCE: InnerWorkings sees FY2017 EPS of $0.44-$0.47. InnerWorkings sees FY2017 revenue of $1.155-1.185 billion.
IPCI Intellipharmaceutics International (IPCI) said it received final Food and Drug Administration approval for an abbreviated new drug application filed for metformin hydrochloride extended release tablets. The drugmaker said its newly-approved product is a generic equivalent to Bristol-Myers Squibb's (BMY) glucophage and is indicated for use in managing type 2 diabetes treatment.
JWN Nordstrom (JWN) reported Q4 EPS of $1.37, $0.22 better than the analyst estimate of $1.15. Revenue for the quarter came in at $4.24 billion versus the consensus estimate of $4.35 billion.
PACD Pacific Drilling (PACD) announced a net loss for fourth-quarter 2016 of $43.0 million or $2.03 per diluted share, compared to net income for third-quarter 2016 of $0.2 million or $0.01 per diluted share. Net loss for fourth-quarter 2015 was $13.6 million or $0.64 per diluted share. Net loss for full-year 2016 was $37.2 million or $1.76 per diluted share, compared to net income for full-year 2015 of $126.2 million or $5.97 per diluted share.
RH Restoration Hardware (RH) said it expects Q4 GAAP net revenues of approximately $587 million and adjusted net revenues of approximately $590 million. The CapIQ mean was for sales of $584.71 million. EPS are seen approximately $0.21 and adjusted diluted EPS approximately $0.68. Estimates were for adjusted EPS of $0.65 and GAAP EPS of $0.63. Its Board of Directors also authorized a $300 million common share repurchase program.
OLED Universal Display (OLED) reported Q4 EPS of $0.55, $0.13 better than the analyst estimate of $0.42. Revenue for the quarter came in at $74.6 million versus the consensus estimate of $68.6 million.
VUZI Vuzix Corporation (VUZI) announced that the Company has signed an agreement to build a customized pair of smart glasses, for Toshiba Client Solutions Co. Ltd. ( Toshiba ), a wholly owned subsidiary of Toshiba Corporation . Based in Tokyo , Toshiba Corporation is a world leader and innovator in pioneering high technology, a diversified manufacturer and marketer of advanced electronic and electrical products covering consumer, enterprise, industrial and infrastructure markets. Toshiba Corporation is one of the largest electronics and technology companies in the world.
Copyright dailystockplays.com All Rights Reserved